Searched for
CEQUA
Sun Pharma most exposed Indian company to Trump's new tariff threat, warns JefferiesIndian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while g...- Sun Pharma Q2 Preview: PAT may rise 2% YoY; Leqselvi spending to weigh on marginsSun Pharma is expected to report modest Q2 FY26 earnings growth, with PAT likely up 2% YoY and revenue rising 7%. Analysts cite Leqselvi la...
- Sun Pharma Q3 preview: Consolidated PAT may rise 8% YoY amid moderate revenue growthSun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with moderate sales in the US and Indi...
- Sun Pharma, Aurobindo recall drugs from US marketSun Pharmaceutical Industries and Aurobindo Pharma are recalling products from the US market due to manufacturing issues. Sun Pharma's subs...
- Sun Pharma Q1 preview: Weak Taro show, soft US sales to weigh on earningsConsolidated net profit is seen declining 1.4% YoY to Rs 2,033 crore. India’s largest pharmaceutical company by market capitalization is sc...
- Sun Pharma launches novel therapy for dry eye disease in IndiaDED is caused when the quantity or quality of tears fails to keep the surface of the eye properly lubricated, and associated with symptoms ...
- Buy Sun Pharmaceutical Industries, target price Rs 1180: JM FinancialSun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 254653.42 Crore) opera...
- Buy Sun Pharmaceutical Industries, target price Rs 1130: JM FinancialSun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 213972.69 Crore) opera...
- Better pill! Jefferies gives a double upgrade to Sun Pharma stockSun Pharma performance has been a mixed bag in the near term as the shares dropped 13 per cent in the last month, whereas rose close to 7 p...
- Sun Pharma launches dry eye treatment product in CanadaThe product is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the b...
- Most analysts raise target prices on Sun Pharma after strong Q2CLSA, which raised the target price on Sun Pharma the most, said the drug maker's results were above estimates with key geographies perform...
- Stock Analysis: One-off blues no reason to give up on Sun PharmaAnalysts have cut their price targets marginally following the hit on bottom line.
- Sun Pharma posts Q2 profit of Rs 1,064 crore, meets Street estimatesThe drug maker had reported a loss of Rs 269.60 crore in the corresponding quarter last year.
- CLSA retains buy on Sun Pharma, target price Rs 540Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 540.0 .
- Sun Pharma launches Cequa to treat dry eye disease in USOne of the company's wholly-owned subsidiaries has commercialised Cequa 0.09 per cent in the US, Sun Pharma said in a filing to BSE.
- Buy Sun Pharmaceutical Industries, target Rs 520: CLSASun Pharma is a largecap company, operating in pharmaceuticals and health care sector.
- Buy Sun Pharmaceutical Industries, target Rs 581: Nirmal Bang Institutional EquitiesBuy Sun Pharmaceutical Industries at a price target of Rs 581.
- Sun Pharma Q3 profit jumps fourfold to Rs 1,242 crore, beats Street estimatesThe company had reported Rs 321.57 crore profit in the same quarter last year.
- Sun Pharma receives USFDA nod ophthalmic solution used to treat dry eye diseaseNew Delhi, Aug 16 () Sun Pharma has received approval from the US health regulator for CEQUA (cyclosporine ophthalmic solution), used to in...
- Sun Pharma climbs 2% on USFDA approvalThe drug in question is CEQUA (cyclosporine ophthalmic solution) 0.09 per cent.
Load More
